Gene expression profiling predicts clinical outcome of breast cancer.

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Breast cancer patient outcomes vary significantly despite similar disease stages.
• Current predictors like lymph node status and histological grade have limited accuracy in classifying tumor behavior.
• Existing gene expression signatures do not facilitate personalized therapy strategies.

Purpose of the Study:

• To identify a gene expression signature predictive of distant metastasis in lymph node-negative breast cancer patients.
• To develop a signature for identifying tumors in BRCA1 carriers.
• To improve patient-tailored therapy strategies for breast cancer.

Main Methods:

• DNA microarray analysis was performed on primary breast tumors from 117 young patients.
• Supervised classification was applied to identify predictive gene expression signatures.
• The study focused on identifying a 'poor prognosis' signature and a BRCA1 carrier signature.

Main Results:

• A gene expression signature, termed the 'poor prognosis' signature, was identified, predicting a short interval to distant metastases.
• This signature comprises genes involved in cell cycle, invasion, metastasis, and angiogenesis.
• A distinct signature was established for identifying tumors of BRCA1 carriers.

Conclusions:

• The identified gene expression profile significantly outperforms current clinical parameters in predicting breast cancer disease outcome.
• This predictive signature offers a strategy for selecting patients who would benefit from adjuvant therapy.
• Findings pave the way for more precise, patient-tailored treatment approaches in breast cancer management.